Stocks · News reference
Artelo Biosciences to Present ART27.13 Data at IASP 2026 World Congress on Pain
Artelo Biosciences announced it will present nonclinical data for ART27.13, a candidate for chemotherapy-induced neuropathic pain, at the IASP 2026 World Congress on Pain.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Artelo Biosciences to Present Data on ART26.12 at IASP 2026 World Congress on Pain
Artelo Biosciences announced that Professor Saoirse O'Sullivan will present data on its lead FABP5 inhibitor, ART26.12, at the IASP 2026 World Congress on Pain in Bangkok.
8-K filing — ARTELO BIOSCIENCES, INC. (ARTL)
Filed: 2026-10-09 AccNo: 0001640334-26-001665 Size: 143 KB Item 8.01: Other Events
Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000
U.S. stocks fell Thursday as tech slid; jobless claims beat estimates. Oil rose, while APUS surged 245% and BENF plunged 33%.
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
Artelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?
Artelo Biosciences, Inc. (NASDAQ: ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering its drug candidate ART27.13 for the treatment of obesity.